Judit Bassols

Dr. Judit Bassols

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2016 in Pediatric Research
Verified
Journal Article
Closed access
JBJudit Bassols
Judit Bassols
Matteo SerinoMatteo Serino
Matteo Serino
GCGemma Carreras-Badosa
Gemma Carreras-Badosa
RBRémy Burcelin
Rémy Burcelin
VBVincent Blasco-Baque
Vincent Blasco-Baque
JFJosé M. Fernandez-Real
José M. Fernandez-Real

1 December 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JBJudit Bassols
Judit Bassols
APAnna Prats-Puig
Anna Prats-Puig
PSPilar Soriano-Rodríguez
Pilar Soriano-Rodríguez
MGMaría Mar García-González
María Mar García-González
JRJoanna Reid
Joanna Reid
ALAbel López-Bermejo
Abel López-Bermejo
Context: A lower free T4 (fT4), within the euthyroid range, has been shown in adults to associate with an adverse metabolic phenotype. Thyroid physiology changes significantly during gestation and affects maternal and fetal well-being. Objective: The aim of the study was to test the hypothesis that a lower serum fT4 in healthy euthyroid pregnant women is related to a less favorable metabolic phenotype and to fetal or placental weight. Design, Setting, Patients, and Outcome Measures: We examined associations of thyroid function tests (TSH and fT4) and the free T3 (fT3)-to-fT4 ratio (as a proxy of deiodinase activity) with a metabolic profile [preload and postload glucose, glycosylated hemoglobin (HbA1c), high molecular-weight (HMW)-adiponectin, homeostasis model of assessment for insulin resistance (HOMA-IR), and serum lipids] in 321 healthy pregnant women. All women were euthyroid and had negative anti-thyroid peroxidase antibodies. None received thyroid hormone replacement. Blood tests were performed in women between 24 and 28 wk gestation. Placentas and newborns were weighed at birth. Results: Circulating TSH did not relate to metabolic parameters, but decreasing fT4 and increasing fT3-to-fT4 ratio associated with a less favorable metabolic phenotype, as judged by higher postload glucose, HbA1c, fasting insulin, HOMA-IR, and triglycerides, and by a lower HMW-adiponectinemia (all P ≤ 0.005). In multiple regression analyses, fT4 was independently associated with HbA1c (β = −0.135; P = 0.038), HMW-adiponectin (β = 0.218; P < 0.001), and placental weight (β = −0.185; P < 0.005), whereas the fT3-to-fT4 ratio was independently associated with maternal body mass index (β = 0.265; P < 0.001), HMW-adiponectinemia (β = −0.237; P < 0.002), HOMA-IR (β = 0.194; P = 0.014), and placental weight (β = 0.174; P = 0.020). Conclusion: In pregnant women without a history of thyroid dysfunction, lower concentrations of fT4 and a higher conversion of fT4 to fT3, as inferred by changes in the fT3-to-fT4 ratio, were found to be associated with a less favorable metabolic phenotype and with more placental growth.

1 October 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
José María Moreno-NavarreteJosé María Moreno-Navarrete
José María Moreno-Navarrete
FOFrancisco Jose Ortega
Francisco Jose Ortega
JBJudit Bassols
Judit Bassols
WRW. Ricart
W. Ricart
JFJosé M. Fernandez-Real
José M. Fernandez-Real
Context: Lactoferrin is an innate immune system protein with multiple beneficial health activities. Objective: To gain insight in the interaction between innate immune system and metabolic disturbances (obesity and insulin resistance), we investigated the relationship between circulating lactoferrin and chronic inflammation-associated insulin resistance according glucose tolerance status in Caucasian population. Design, Setting, Participants, and Main Outcome Measures: Circulating nonstressed lactoferrin (ELISA), metabolic variables, and inflammatory markers were measured in 229 men, 94 with normal (NGT) and 135 with altered glucose tolerance (AGT). Lactoferrin secretion by neutrophil was investigated in whole-blood culture (four young NGT subjects, four older NGT subjects, and four patients with type 2 diabetes) under microbial lipopolysaccharide (LPS) with IL-6 and rosiglitazone treatment. We also tested the lactoferrin action in THP-1 cells under LPS stimulus. Results: Circulating lactoferrin was significantly decreased in patients with AGT (431.5 ± 187.5 vs. 493.5 ± 238.9 ng/ml, P = 0.02). In addition, circulating lactoferrin was negatively associated with hyperglycemia and obesity measures and positively with insulin sensitivity. Lactoferrin was negatively related to inflammatory markers, especially in AGT subjects. In ex vivo experiments, we found a significant decrease in LPS-induced lactoferrin release from neutrophils in subjects with type 2 diabetes. IL-6 coincubation decreased LPS-induced lactoferrin release in NGT subjects (P < 0.001). Finally, rosiglitazone treatment led to increased lactoferrin secretion (398 ± 193 vs. 280.1 ± 104.9 ng/ml, P < 0.0001). Lactoferrin decreased nuclear factor-κβ activation and IL-6, IL-8, and macrophage chemoattractant protein-1 expression under LPS challenge. Conclusions: Decreased circulating lactoferrin levels may play a role in chronic low level inflammation-associated insulin resistance. Reduced lactoferrin production in neutrophils of patients with type 2 diabetes is associated with insulin resistance and central obesity.

1 November 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
GCGemma Carreras-Badosa
Gemma Carreras-Badosa
ABAlexandra Bonmatí
Alexandra Bonmatí
FOFrancisco Jose Ortega
Francisco Jose Ortega
JMJosep-Maria Mercader
Josep-Maria Mercader
MGMarta Guindo-Martínez
Marta Guindo-Martínez
JBJudit Bassols
Judit Bassols
Context: MicroRNAs (miRNAs) are valuable circulating biomarkers and therapeutic targets for metabolic diseases. Objective: The objective of the study was to define the pattern of circulating miRNAs in pregestational and gestational obesity and to explore their associations with maternal metabolic parameters and with markers for pre- and postnatal growth. Design, Settings, and Main Outcome Measure: TaqMan low-density arrays were used to profile plasma miRNAs in six women with pregestational obesity (PregestOB), six with gestational obesity (GestOB), and six with normal pregnancies (control) during the second trimester of gestation. The most relevant miRNAs were validated in 70 pregnant women (20 PregestOB, 25 GestOB, and 25 control). Maternal metabolic parameters including glucose, glycated hemoglobin, homeostasis model assessment index of insulin resistance, C-peptide, and lipids were assessed. Placentas were weighed at delivery and newborns also during 6 months of life. Results: We identified 13 circulat...

1 October 2004 in Theriogenology
Verified
Journal Article
Closed access
SSS. Sancho
S. Sancho
Elisabeth PinartElisabeth Pinart
Elisabeth Pinart
MBM. Briz
M. Briz
NGN. Garcia-Gil
N. Garcia-Gil
EBE. Badia
E. Badia
SBSergi Bonet
Sergi Bonet

12 November 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MZMin Zhao
Min Zhao
ALAbel López-Bermejo
Abel López-Bermejo
CCCarmelo A. Caserta
Carmelo A. Caserta
CMCarla Campos Muniz Medeiros
Carla Campos Muniz Medeiros
Anastasios KolliasAnastasios Kollias
Anastasios Kollias
MRMilena Cavalcanti Ramalho
Milena Cavalcanti Ramalho
OBJECTIVE: It has been argued that metabolically healthy obesity (MHO) does not increase cardiovascular disease (CVD) risk. This study examines the association of MHO with carotid intima-media thickness (cIMT), a proxy of CVD risk, in children and adolescents. RESEARCH DESIGN AND METHODS: Data were available for 3,497 children and adolescents aged 6–17 years from five population-based cross-sectional studies in Brazil, China, Greece, Italy, and Spain. Weight status categories (normal, overweight, and obese) were defined using BMI cutoffs from the International Obesity Task Force. Metabolic status (defined as “healthy” [no risk factors] or “unhealthy” [one or more risk factors]) was based on four CVD risk factors: elevated blood pressure, elevated triglyceride levels, reduced HDL cholesterol, and elevated fasting glucose. High cIMT was defined as cIMT ≥90th percentile for sex, age, and study population. Logistic regression model was used to examine the association of weight and metabolic status with high cIMT, with adjustment for sex, age, race/ethnicity, and study center. RESULTS: In comparison with metabolically healthy normal weight, odds ratios (ORs) for high cIMT were 2.29 (95% CI 1.58–3.32) for metabolically healthy overweight and 3.91 (2.46–6.21) for MHO. ORs for high cIMT were 1.44 (1.03–2.02) for unhealthy normal weight, 3.49 (2.51–4.85) for unhealthy overweight, and 6.96 (5.05–9.61) for unhealthy obesity. CONCLUSIONS: Among children and adolescents, cIMT was higher for both MHO and metabolically healthy overweight compared with metabolically healthy normal weight. Our findings reinforce the need for weight control in children and adolescents irrespective of their metabolic status.